Shopping Cart (Login required)

Press Releases

Language

Year

Wed, 31 Aug 2016 15:00:00 +0200

Biotage invests in biomolecule purification

Thu, 11 Aug 2016 08:30:00 +0200

Interim report January - June 2016

Wed, 01 Jun 2016 09:00:00 +0200

Biotage AB (publ) – board member Anders Walldov leaves his assignments

Fri, 29 Apr 2016 09:00:00 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 28, 2016

Fri, 29 Apr 2016 09:00:00 +0200

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
Thu, 28 Apr 2016 15:00:00 +0200

Interim report  January - March 2016

Tue, 22 Mar 2016 09:00:00 +0100

Biotage AB (publ) publishes its 2015 Annual Report and Corporate Governance Report and Financial Goals for the period 2016 – 2018

Tue, 22 Mar 2016 09:00:00 +0100

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB (publ)

Thu, 11 Feb 2016 08:30:00 +0100

Year-end report for 2015

Wed, 16 Dec 2015 08:00:00 +0100

Information regarding Biotage’s Annual Report 2014

Fri, 30 Oct 2015 08:30:00 +0100

Interim report for the period January - September 2015

Tue, 20 Oct 2015 10:00:00 +0200

Biotage appoints Nomination Committee

Mon, 21 Sep 2015 08:30:00 +0200

Biotage and CEO Torben Jörgensen have agreed to extend period of service

Thu, 13 Aug 2015 08:30:00 +0200

Interim report January - June 2015

Tue, 16 Jun 2015 08:30:00 +0200

Biotage continued success in re-examination proceedings

US Patent and Trademark Office will issue reexamination certificates rejecting all claims in US patents 7,138,061, 7,381,327 and 7,410,571.
Wed, 29 Apr 2015 08:30:00 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 28, 2015

Wed, 29 Apr 2015 08:30:00 +0200

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
Tue, 28 Apr 2015 13:00:00 +0200

Interim report  January - March 2015

Thu, 26 Mar 2015 08:30:00 +0100

Biotage AB (publ) publishes its 2014 Annual Report and Corporate Governance Report and new Financial Goals

Thu, 26 Mar 2015 08:30:00 +0100

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB (publ)

Thu, 12 Feb 2015 08:30:00 +0100

Year-end report for 2014

Thu, 30 Oct 2014 08:30:00 +0100

Interim report for the period January - September 2014

Thu, 23 Oct 2014 11:00:00 +0200

Biotage appoints Nomination Committee and publishes financial calendar 2014 and 2015

Thu, 11 Sep 2014 14:00:00 +0200

Biotage success in re-examination proceedings

– U.S. Court of Appeals for the Federal Circuit have affirmed US Patent and Trademark Office’s Patent Trial and Appeal Board decisions to reject all claims in US patents 7,138,061, 7,381,327 and 7,410,571.
Thu, 14 Aug 2014 08:30:00 +0200

Interim report for the period January – June 2014

Wed, 30 Apr 2014 14:15:00 +0200

Biotage AB – changes in number of shares and votes

Mon, 28 Apr 2014 18:41:23 +0200

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
Mon, 28 Apr 2014 18:33:15 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 28, 2014

Mon, 28 Apr 2014 15:00:00 +0200

Interim report  January - March 2014

Wed, 26 Mar 2014 09:00:00 +0100

Biotage AB (publ) publishes its 2013 Annual Report and Corporate Governance Report

Wed, 26 Mar 2014 09:00:00 +0100

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB (publ)

Thu, 13 Feb 2014 08:30:00 +0100

Year-end report for 2013

Fri, 25 Oct 2013 08:30:00 +0200

Interim report for the period January - September 2013

Thu, 26 Sep 2013 14:00:00 +0200

Biotage AB Nomination Committee

Thu, 15 Aug 2013 08:30:00 +0200

Interim report for the period January - June 2013

Fri, 14 Jun 2013 09:06:23 +0200

Biotage AB (publ) – disclosure notice of substantial holding of shares

Fri, 31 May 2013 08:24:45 +0200

Biotage AB – changes in number of shares and votes

Fri, 26 Apr 2013 13:00:00 +0200

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
Thu, 25 Apr 2013 17:30:34 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 25, 2013

Thu, 25 Apr 2013 15:00:00 +0200

Interim report January - March 2013

Thu, 04 Apr 2013 09:00:00 +0200

Biotage AB (publ) publishes its 2012 Annual Report, Corporate Governance Report and new financial goals

Mon, 25 Mar 2013 08:00:00 +0100

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB (publ)

Mon, 04 Mar 2013 10:00:00 +0100

Food contact notification to FDA

Biotage AB (publ) through its subsidiary MIP Technologies AB submits Food Contact Notification (FCN) to U.S. Food and Drug Administration (FDA)
Tue, 12 Feb 2013 08:00:00 +0100

Year-end report for 2012

Wed, 16 Jan 2013 08:00:00 +0100

Biotage success in re-examination proceedings

– US Patent and Trademark Office’s Patent Trial and Appeal Board have affirmed the Examiner’s decisions to reject all claims in US patents 7,138,061, 7,381,327 and 7,410,571.
Fri, 26 Oct 2012 08:00:00 +0200

Interim report for the period January - September 2012

Tue, 16 Oct 2012 08:00:00 +0200

Biotage AB Nomination Committee

Fri, 17 Aug 2012 08:00:00 +0200

Interim report January - June 2012

Tue, 05 Jun 2012 09:00:00 +0200

Biotage AB changes in number of shares and votes

Fri, 27 Apr 2012 09:00:00 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 26, 2012

Fri, 27 Apr 2012 09:00:00 +0200

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
Thu, 26 Apr 2012 15:22:20 +0200

Interim report January - March 2012

Thu, 05 Apr 2012 09:00:00 +0200

Biotage AB (publ) publishes its 2011 Annual Report and Corporate Governance Report

Thu, 29 Mar 2012 09:00:00 +0200

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB (publ)

Mon, 13 Feb 2012 16:02:00 +0100

Correction – Biotage AB (publ) – disclosure notice of substantial holding of shares

Mon, 13 Feb 2012 14:07:53 +0100

Biotage AB (publ) – disclosure notice of substantial holding of shares

Thu, 09 Feb 2012 08:00:00 +0100

Year-end report  January - December 2011

Thu, 12 Jan 2012 08:00:00 +0100

Biotage is subject to extended patent litigation in the US

Wed, 26 Oct 2011 08:00:00 +0200

Interim report January - September 2011

Wed, 26 Oct 2011 08:00:00 +0200

Biotage AB Nomination Committee

Wed, 26 Oct 2011 08:00:00 +0200

Changes in Management of Biotage AB

Thu, 08 Sep 2011 09:00:00 +0200

Following Biotage’s request for re-examination US Patent and Trademark Office has rejected all claims in US patent 7,410,571

Wed, 17 Aug 2011 08:00:00 +0200

Interim report January - June 2011

Mon, 09 May 2011 14:00:00 +0200

Following Biotage’s request for re-examination US Patent and Trademark Office has rejected all claims in US patent 7,138,061

Fri, 06 May 2011 08:30:00 +0200

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
Wed, 27 Apr 2011 17:30:00 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 27, 2011

Wed, 27 Apr 2011 14:21:50 +0200

Interim report January - March 2011

Wed, 06 Apr 2011 08:30:00 +0200

Biotage AB (publ) publishes its 2010 Annual Report

Fri, 25 Mar 2011 09:00:00 +0100

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB (publ)

Wed, 16 Mar 2011 13:00:00 +0100

Following Biotage’s request for re-examination US Patent and Trademark Office has rejected all claims in US patent 7,381,327

Thu, 10 Feb 2011 08:30:00 +0100

Year-end report January - December 2010

Thu, 04 Nov 2010 12:00:00 +0100

Biotage AB (publ) – disclosure notice of substantial holding of shares

Wed, 27 Oct 2010 16:24:51 +0200

Biotage AB Nomination Committee

Wed, 27 Oct 2010 10:30:00 +0200

Biotage AB (publ) – board member Staffan Lindstrand leaves his assignment

Tue, 26 Oct 2010 12:22:16 +0200

Interim report January - September 2010

Fri, 13 Aug 2010 08:30:00 +0200

Interim report January - June 2010

Thu, 01 Jul 2010 08:30:00 +0200

Biotage AB (publ) – disclosure notice of substantial holding of shares

Mon, 31 May 2010 09:21:29 +0200

Biotage appoints Anders Wikström as Vice President of Operations and Anthony Rees as Chief Scientific Officer

Anders Wikström has been responsible for Biotage’s Research and Development since 2007. Anthony Rees has been CEO of MIP Technolgies, which was recently acquired by Biotage.
Mon, 24 May 2010 08:30:00 +0200

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
Tue, 18 May 2010 08:30:00 +0200

Biotage AB Acquires SPE Extraction and Evaporation Products from Caliper Life Sciences, Inc.

Fri, 30 Apr 2010 09:00:05 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 29, 2010

Thu, 29 Apr 2010 14:02:00 +0200

Interim report January - March 2010

Mon, 26 Apr 2010 08:30:00 +0200

Biotage AB Acquires MIP Technologies AB, Developer of Molecularly Imprinted Polymer Technology

Thu, 08 Apr 2010 08:00:00 +0200

Biotage AB (publ) publishes its 2009 Annual Report

Wed, 31 Mar 2010 08:30:00 +0200

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB

Wed, 17 Feb 2010 08:25:00 +0100

Unique Parallel Peptide Synthesizer with Automated Microwave Technology offers “The Best of Both Worlds” for Peptide Chemists

Thu, 11 Feb 2010 08:15:00 +0100

Year-end report January - December 2009

Mon, 11 Jan 2010 08:00:00 +0100

Sale of Biotage’s facility in Charlottesville, Virginia

Wed, 16 Dec 2009 09:05:00 +0100

Biotage moves to 100% direct sales for SPE products in the UK

Tue, 27 Oct 2009 08:30:00 +0100

Interim report January-September 2009

Mon, 19 Oct 2009 11:40:00 +0200

Biotage AB Nomination Committee

Fri, 14 Aug 2009 08:05:00 +0200

Interim report for Biotage January - June 2009

Mon, 22 Jun 2009 11:25:00 +0200

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
Tue, 28 Apr 2009 07:05:00 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 27, 2009

Mon, 27 Apr 2009 15:14:00 +0200

Interim report January – March 2009

Wed, 22 Apr 2009 08:40:00 +0200

Biotage is subject to patent litigation in the US

Wed, 08 Apr 2009 08:30:00 +0200

Biotage AB (publ) releases its 2008 Annual Report

Fri, 27 Mar 2009 09:00:00 +0100

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB

Tue, 17 Feb 2009 10:37:00 +0100

Biotage AB joins forces with MultiSynTech GmbH and enters the peptide synthesis business

Biotage today announced that the company will enter the peptide synthesis business, through two new agreements with German company MultiSynTech GmbH. The agreements concern both the distribution rights for MultiSynTech’s systems and the establishment of a joint development project.
Tue, 10 Feb 2009 08:59:33 +0100

Year-end report 2008

Thu, 22 Jan 2009 15:15:00 +0100

Biotage takes yet another step in streamlining efforts

– outsources all instrument production to contract manufacturers Biotage has made the decision to transfer instrument production from its Charlottesville, VA factory in the U.S. to a contract manufacturer. Through this decision, the company takes yet another step to increase efficiency in business activities. Biotage expects this measure to enable substantial cost savings, a reduction in tied-up capital and increased flexibility.
Fri, 21 Nov 2008 10:35:00 +0100

Resolutions at the Extraordinary General Meeting in Biotage AB on November 21, 2008

Thu, 06 Nov 2008 09:30:00 +0100

NOTICE OF EXTRAORDINARY GENERAL MEETING IN BIOTAGE AB

Fri, 31 Oct 2008 08:29:59 +0100

The Board of Directors proposes an increase in unappropriated funds through a reduction of the statutory reserve

Fri, 31 Oct 2008 08:28:41 +0100

Interim report January - September 2008

Fri, 17 Oct 2008 13:44:24 +0200

Biotage AB Nomination Committee

Wed, 01 Oct 2008 08:20:29 +0200

Biotage Divests Biosystems Division to QIAGEN

As a result of the Strategic Review of Biotage’s entire operations, launched in October 2007, the Board of Biotage AB (“Biotage”) has concluded to divest the Biosystems division (“Biosystems”) and the shares in Corbett Life Science Pty Ltd (“Corbett”) to QIAGEN. The transaction is expected to close on October 2, 2008. Biotage will focus its future activities on the Discovery Chemistry division with attention to improving the operating margin, creating organic growth and acquire complementary products or businesses.
Fri, 15 Aug 2008 08:20:20 +0200

Interim report January - June 2008

Wed, 30 Apr 2008 09:59:40 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 29, 2008

Tue, 29 Apr 2008 07:54:43 +0200

Interim report January – March 2008

Tue, 01 Apr 2008 09:17:10 +0200

The Dept of Pathology at the Uppsala University Hospital evaluates Biotage’s new Pyrosequencing® platform for clinical diagnostics in oncology

Mon, 31 Mar 2008 08:00:00 +0200

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB

Tue, 04 Mar 2008 09:21:20 +0100

Biotage AB and McMaster University sign two year extension to Molecular Imaging Development Agreement.

Tue, 19 Feb 2008 08:30:00 +0100

Biotage AB Increases Focus on Environmental Market Segments

Thu, 07 Feb 2008 08:15:00 +0100

Year-end report 2007

Thu, 25 Oct 2007 08:53:58 +0200

Interim report January – September 2007

Mon, 08 Oct 2007 14:26:46 +0200

Biotage AB Nomination Committee

Tue, 14 Aug 2007 08:57:04 +0200

Interim report January – June 2007

Tue, 19 Jun 2007 10:16:23 +0200

Biotage open up new business area – Molecular Imaging

Molecular Imaging is an emerging market that is playing an important role to the ongoing worldwide efforts at improving health care and cost saving in the Pharma Industry. Biotage entered into a Molecular Imaging collaboration with McMaster University in February 2007 and it has ever since become more and more apparent that Biotage is significantly well positioned to become an important player within this industry. Biotage has decided to establish itself in Molecular Imaging to leverage on and take full advantage of its product offerings in this challenging new business area.
Fri, 27 Apr 2007 14:54:32 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 26, 2007

Thu, 26 Apr 2007 14:08:54 +0200

Interim report January – March 2007

Tue, 24 Apr 2007 09:58:15 +0200

Biotage AB and Shanghai Chempartner Co., Ltd. sign multi-instrument deal

Fri, 23 Mar 2007 09:40:15 +0100

Notice of Annual General Meeting in Biotage AB

Thu, 22 Mar 2007 14:49:47 +0100

Biotage – Change of security type

Wed, 21 Mar 2007 08:30:18 +0100

Proposals for Annual General Meeting

The Board of Directors of Biotage AB proposes the Annual General Meeting on April 26, 2007, to: authorize the Board to issue shares and/or convertibles resolve on the adoption of a global employee stock option program resolve on a hedging arrangement for the adoption of the employee stock option program (authorization for the Board to issue warrants)
Mon, 26 Feb 2007 10:30:21 +0100

Biotage AB and McMaster University sign joint agreement to develop new chemistry platform to speed the production of molecular imaging and therapy agents.

Mon, 12 Feb 2007 09:53:35 +0100

Global Stock Option Program Biotage Employees

The board of directors has, in accordance with an authorization from the annual shareholders meeting held on April 27, 2006, adopted a global stock option program for employees within the Biotage group - Biotage AB Global Share Option Plan 2006.
Fri, 09 Feb 2007 12:21:57 +0100

Year-end report 2006

Biotage achieves profit for the full year and continues its positive profit development in the fourth quarter
Mon, 23 Oct 2006 11:22:32 +0200

Interim report January – September 2006

Biotage reports its best result ever
Tue, 08 Aug 2006 11:05:00 +0200

Interim report January – June 2006

Thu, 27 Apr 2006 18:36:12 +0200

Resolutions at the Annual Shareholders’ Meeting in Biotage AB on April 27, 2006

Thu, 27 Apr 2006 15:29:22 +0200

Interim report January – March 2006

Fri, 07 Apr 2006 08:00:00 +0200

Biotage’s Annual Report 2005 in Swedish published

Tue, 28 Mar 2006 08:53:27 +0200

NOTICE OF ANNUAL GENERAL MEETING OF BIOTAGE AB

UNOFFICIAL TRANSLATION – This notice of the Annual General Meeting was prepared in Swedish and translated into English. In the event of any discrepancies between the Swedish original and the English translation, the former shall have precedence.
Thu, 23 Mar 2006 09:01:11 +0100

Proposals for Annual General Meeting

The Board of Directors of Biotage AB proposes the Annual General Meeting on April 27, 2006, to: • authorize the Board to issue shares and/or convertibles • resolve on the adoption of a global employee stock option program • resolve on a hedging arrangement for the adoption of the employee stock option program (authorization for the Board to issue warrants)
Tue, 28 Feb 2006 09:15:06 +0100

Biotage Makes a Change in Top Management after Business Area President resigns

Wed, 22 Feb 2006 09:16:08 +0100

Global option program for employees in Biotage

Thu, 09 Feb 2006 14:24:46 +0100

Torben Jörgensen New CEO at Biotage

Thu, 09 Feb 2006 14:24:22 +0100

Year-End Report 2005

Fourth Quarter and Full Year Results 2005
Thu, 12 Jan 2006 15:03:13 +0100

Biotage AB acquires rights to novel Evaporation system from Vapourtec, Ltd.

Wed, 19 Oct 2005 08:30:00 +0200

Interim report January – September 2005

Thu, 06 Oct 2005 09:00:00 +0200

Biotage AB Acquires Separtis Holding AG for 1.4M Euros (13M SEK) and Completes EU Distribution Consolidation

Tue, 13 Sep 2005 08:34:44 +0200

Biotage resolves upon a rights issue

Thu, 08 Sep 2005 09:34:56 +0200

Biotage issues 10 million new shares and intends to execute a rights issue

Mon, 05 Sep 2005 17:18:17 +0200

Biotage receives an order for multiple cGMP HPLC systems

Tue, 30 Aug 2005 19:56:16 +0200

Resolutions at the Extraordinary General Meeting in Biotage AB on August 30, 2005

Thu, 11 Aug 2005 13:00:00 +0200

Biotage has received its largest order to date

Fri, 05 Aug 2005 15:15:53 +0200

Extraordinary General Meeting

Thu, 28 Jul 2005 13:19:04 +0200

Interim report January – June 2005

Fri, 01 Jul 2005 08:30:00 +0200

Biotage issues further 3.4 million new shares

Tue, 28 Jun 2005 08:30:47 +0200

Biotage issues 3 million new shares

Thu, 02 Jun 2005 08:45:00 +0200

Biotage’s acquisition of Argonaut approved by Argonaut’s shareholders

Wed, 04 May 2005 12:02:00 +0200

Biotage’s acquisition of the American company Argonaut Technologies: Final decision at a special shareholders’ meeting on June 1, 2005

Wed, 27 Apr 2005 18:58:08 +0200

Resolutions at the Annual General Meeting in Biotage AB on April 27, 2005

At the Annual General Meeting held in Biotage AB (corporate registration no. 556539-3138) on April 27, 2005, the following resolutions were passed, among others.
Wed, 27 Apr 2005 16:26:28 +0200

Interim report January – March 2005

• Sales in the first quarter 2005 amounted to 72.0 MSEK (87.0) • The operating result for the first quarter amounted to –22.2 MSEK (22.7) • The result after tax for the first quarter amounted to -13.5 MSEK (-21.2) • Earnings per share for the first quarter amounted to –0.21 SEK (-0.37) • During the first quarter Biotage announced its intention to acquire the reagents and process instruments business of the American company Argonaut Technologies Inc. The purchase price amounts to 145 MSEK (21.2 MUSD). This will give Biotage additional sales of approx. 125 MSEK. The acquisition must receive final approval by a general meeting of the shareholders in Argonaut Technologies Inc. Through the acquisition Biotage will get a complete product portfolio in microwave synthesis, purification systems and reagents. • This interim report has been prepared in accordance with International Financial Reporting Standards (IFRS) and is the first financial report prepared by Biotage according to IFRS. A brief description of the transition to IFRS and its effects is presented separately.
Fri, 08 Apr 2005 08:30:00 +0200

Biotage’s Annual Report 2004 in Swedish published

The Biotage Annual Report for 2004 in Swedish is available as a PDF file on the Group’s web site as of today, at www.biotage.com. The printed Swedish version is now being distributed to the shareholders and can also be ordered from Biotage at telephone +46 18 56 59 00. The English edition of the Annual Report will be available in a few weeks.
Wed, 23 Mar 2005 15:52:17 +0100

NOTICE OF ANNUAL GENERAL MEETING OF BIOTAGE AB

Tue, 22 Mar 2005 18:01:35 +0100

Proposals for Annual General Meeeting

The Board of Directors of Biotage AB proposes the Annual General Meeting on April 27, 2005, to: • authorize the Board to issue ordinary shares and/or convertible bonds • resolve on the implementation of a global employee stock option program • resolve on a hedging arrangement for the implementation of the employee stock option program (authorization for the Board to issue debentures with detachable warrants)
Fri, 18 Mar 2005 08:57:19 +0100

Biotage broadens its acquisition of American Argonaut Technologies’ reagents business to include all of Argonaut’s business

On February 22 2005 Biotage announced its intention to acquire the reagents business of the American company Argonaut Technologies Inc. Through this acquisition, Biotage strengthens its product offering in medicinal chemistry and gets a complete product portfolio of microwave synthesis, cleanup and purification systems and consumables, which will enable faster and more efficient development of new drug candidates. Today Biotage announces that the agreement is broadened to include also the process instrument business, so that all Argonaut’s business is acquired. The sales price amounts to 145 MSEK (21.2 MUSD). Last year Argonaut reported reagents sales of about 100 MSEK. The process instrument sales amounted to about 40 MSEK, 25 million of which emanated from products which Biotage intends to continue. Biotage will thus increase its sales by approx. 125 MSEK.
Tue, 22 Feb 2005 07:30:00 +0100

Biotage acquires Argonaut Technologies Consumable Division

– strengthens its position in Medicinal Chemistry Biotage acquires the Consumable Division of the US company Argonaut Technologies Inc. Through the acquisition, Biotage strengthens its position in Medicinal Chemistry and gives the company a complete product portfolio of Microwave Synthesis, Cleanup and Purification Systems and Consumables, which will enable faster and more efficient development of new product candidates. The acquired division reported sales of about 100 million SEK (13-14 million USD) in 2004. The sales price amounts to about 139 million SEK (19,9 MUSD).
Wed, 09 Feb 2005 15:02:31 +0100

Year-End Report 2004, Biotage AB

Year-End Report January – December 2004 (Figures in brackets refer to the outcome 2003 and pro-forma 2003, respectively) • The financial targets were achieved: – Operating costs were reduced by more than 50 percent in 2004 and amounted to 278.9 MSEK, compared to 607.8 MSEK pro-forma for 2003. – The cash flow after investments was positive in the fourth quarter, amounting to 1.0 MSEK. – Operating profit before goodwill amortization was positive in the fourth quarter and amounted to 0.9 MSEK. • Sales in 2004 amounted to 366.6 MSEK (173.7 MSEK and 362.0 MSEK). At constant exchange rates sales would have amounted to 392.9 MSEK, corresponding to an increase by 8 percent compared to last year’s pro-forma sales. • Sales in the fourth quarter amounted to 106.2 MSEK (105.1 and 112.1 MSEK. At constant exchange rates sales would have amounted to 114.1 MSEK, corresponding to an increase by 2 percent compared to last year’s pro-forma sales. • The operating result for 2004 improved to –102.1 MSEK (-261.2 and –442.4 MSEK). • The result after tax for 2004 amounted to -115.0 MSEK (-244.4 MSEK and -425.8 MSEK) • Earnings per share in 2004 amounted to -1.99 SEK (-6.02 SEK and -7.37 SEK). • A new share issue to Catella Healthcare in December provided 45 MSEK to Biotage.
Mon, 10 Jan 2005 09:46:52 +0100

Biotage achieves its financial targets for 2004

Positive cash flow and costs more than halved
Mon, 10 Jan 2005 09:08:46 +0100

Biotage achieves its financial targets for 2004

Positive cash flow and costs more than halved
Tue, 21 Dec 2004 18:03:09 +0100

Allotment of employee stock options in Biotage

Contact: Jeff Bork, President and CEO Tel: +46 734 22 16 60 Uppsala, December 21, 2004. At the Annual General Meeting of shareholders held on April 22, 2002, a global employee stock option program was adopted for the employees of the group. The Board has on December 21, 2004 resolved to allot 446,000 employee stock options to 203 persons in accordance with the option program, of which members of the senior management receive a maximum of 10,000 - 30,000 stock options each, members of the junior management receive a maximum of 3,600 - 10,000 stock options each, other members of management and key employees receive a maximum of 1,200 stock options each and other employees receive a maximum of 400 stock options each. The CEO and President of the company has not been allotted any of the employee stock options.
Wed, 15 Dec 2004 08:31:00 +0100

Biotage issues 5.7 million new shares to Catella Healthcare

Contact: Jeff Bork, President and CEO Tel: +46 734-22 16 60 Mikael Widell, Head of Communications, Catella Holding AB Tel: +46 703-11 99 60 Mikael.widell@invics.se Uppsala December 15, 2004. On 14 December 2004, the board of Biotage AB resolved to increase the company’s share capital by means of a new issue of 5.7 million shares to Catella Healthcare AB. The resolution was based on the authorization to the board by the extra ordinary general meeting on 20 July 2004.
Thu, 09 Dec 2004 18:18:26 +0100

Biotage is the 4th fastest growing technology company in Europe

Uppsala 9 December 2004 The auditing company Deloitte has ranked Sweden’s and Europe’s fastest growing technology company 1999-2003. Biotage was placed number one in Sweden a month ago, and number four in Europe with a growth of 13,156 percent.
Thu, 21 Oct 2004 13:29:07 +0200

Biotage Interim report January - September 2004

Tue, 05 Oct 2004 15:32:02 +0200

No sales increase in the third quarter due to delayed deliveries

Fri, 17 Sep 2004 10:25:01 +0200

Biotage expands licence agreement with 454 Corporation

Tue, 31 Aug 2004 14:17:41 +0200

New large orders for Biotage

Thu, 12 Aug 2004 15:55:58 +0200

Interim report January-June 2004

Tue, 20 Jul 2004 12:15:18 +0200

Extraordinary general meeting in Biotage - Authorization to the Board

Wed, 30 Jun 2004 18:00:00 +0200

NOTICE OF EXTRAORDINARY GENERAL MEETING OF BIOTAGE AB

Tue, 29 Jun 2004 08:00:00 +0200

Extraordinary general meeting in Biotage

Mon, 07 Jun 2004 14:31:00 +0200

Biotage receives largest committed order in history

Fri, 07 May 2004 13:28:04 +0200

Biotage releases new product for microwave synthesis

Wed, 28 Apr 2004 19:24:10 +0200

Annual General Meeting 2004 in Biotage AB

Wed, 28 Apr 2004 15:28:49 +0200

Biotage develops according to plan

Mon, 29 Mar 2004 18:05:00 +0200

NOTICE OF ANNUAL GENERAL MEETING OF BIOTAGE AB

Thu, 25 Mar 2004 18:24:25 +0100

Proposal to Biotage's AGM on employee stock options and on authorization

Tue, 23 Mar 2004 12:02:10 +0100

NEW FOCUS FOR PYROSEQUENCING TOWARDS CLINICAL RESEARCH

Wed, 25 Feb 2004 14:06:28 +0100

Biotage granted patent that enables chemists to integrate synthesis and purification

Thu, 19 Feb 2004 15:01:18 +0100

Biotage interim report for the fourth quarter and year-end results 2003

Tue, 23 Dec 2003 09:13:29 +0100

EMPLOYEE STOCK OPTIONS IN BIOTAGE

Thu, 30 Oct 2003 10:45:00 +0100

PYROSEQUENCING FINALIZES ACQUISITION OF BIOTAGE

Thu, 23 Oct 2003 14:15:00 +0200

NEW MANAGEMENT AND NEW NAME FOR PYROSEQUENCING

Thu, 23 Oct 2003 13:42:00 +0200

DECISION ON NEW SHARE ISSUE

Thu, 23 Oct 2003 13:30:00 +0200

Interim report January - September 2003

Tue, 14 Oct 2003 14:51:00 +0200

PYROSEQUENCING ACQUIRES US BIOTAGE

Mon, 29 Sep 2003 11:30:00 +0200

PYROSEQUENCING IMPLEMENTS NEW ORGANIZATION

Wed, 27 Aug 2003 14:30:00 +0200

NEW PRESIDENT AND MANAGEMENT TEAM AT PYROSEQUENCING

Fri, 22 Aug 2003 14:25:00 +0200

Extraordinary General Meeting in Pyrosequencing Regarding the Acquisition of Personal Chemistry

Tue, 19 Aug 2003 12:30:00 +0200

454 Life Sciences Obtains Exclusive License from Pyrosequencing AB to Next Generation Sequencing Technology for Whole Ge

Mon, 31 Mar 2003 14:00:00 +0200

PYROSEQUENCING AND THOMAS JEFFERSON UNIVERSITY TO DEVELOP APPLICATIONS FOR INFLAMMATORY BOWEL DISEASE

Thu, 29 Nov 2001 08:02:00 +0100

GERMAN ARMY BUYS PYROSEQUENCING PSQ®96 SYSTEM TO AID IN FIGHT AGAINST BIOLOGICAL WEAPONS

Mon, 05 Feb 2001 16:14:00 +0100

PYROSEQUENCING AB ANNOUNCES FIRST CUSTOMER IN HIGH THROUGHPUT DNA SEQUENCING PROGRAM